Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
01 Agosto 2023 - 10:05PM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB) today announced that it will report its financial results for
the second quarter ended June 30, 2023, on Thursday, August 10,
2023, after the close of the U.S. financial markets. The
announcement will be followed by a conference call and webcast with
the investment community on Friday, August 11, 2023, at 9:00 a.m.
ET. Participating on the call from Y-mAbs will be Thomas Gad,
Founder, Chairman and Interim Chief Executive Officer, Bo Kruse,
Chief Financial Officer; Sue Smith, Chief Commercial Officer, and
Vignesh Rajah, Chief Medical Officer.
Conference call and webcast
details:
Investors (domestic): |
|
877-407-0792 |
Investors (international): |
|
201-689-8263 |
Conference ID: |
|
13739908 |
|
|
|
To access a live webcast of the update, please
use this link.
About Y-mAbsY-mAbs is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, antibody-based
therapeutic cancer products. In addition to conventional
antibodies, the Company’s technologies include bispecific
antibodies generated using the Y-BiClone platform and the SADA
platform. The Company’s broad and advanced product pipeline
includes one FDA-approved product, DANYELZA® (naxitamab-gqgk),
which targets tumors that express GD2, and one product candidate,
OMBLASTYS® (omburtamab), which targets tumors that express
B7-H3.
Forward-Looking
StatementsStatements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about our business model,
including the Company’s plans and strategies, development,
commercialization and product distribution plans,; expectations
with respect to our products and product candidates including the
potential of DANYELZA and product candidates based on the SADA
technology and the potential benefits thereof; and other statements
that are not historical facts. Words such as ‘‘anticipate,’’
‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’
‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’
“will”, ‘‘would’’, “guidance” and similar expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Our
product candidates and related technologies are novel approaches to
cancer treatment that present significant challenges. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including but not limited to risks associated with our financial
condition and need for additional capital; the risks that actual
results of our restructuring plan and revised business plan
announced in January 2023 will not be as expected; risks associated
with our development work; cost and success of our product
development activities and clinical trials; the risks of delay in
the timing of our regulatory submissions or failure to receive
approval of our drug candidates; the risks related to
commercializing any approved pharmaceutical product including the
rate and degree of market acceptance of our product candidates;
development of our sales and marketing capabilities and risks
associated with failure to obtain sufficient reimbursement for our
products; the risks related to our dependence on third parties
including for conduct of clinical testing and product manufacture;
our inability to enter into partnerships; the risks related to
government regulation; risks related to market approval, risks
associated with protection of our intellectual property rights;
risks related to employee matters and managing growth; risks
related to our common stock, risks associated with global health
crises, such as the COVID-19 pandemic; risks associated with the
military conflict between Russia and Ukraine and sanctions related
thereto; including inflation and uncertain global credit and
capital markets; and other risks and uncertainties affecting the
Company including those described in the "Risk Factors" section
included in our Annual Report on Form 10-K for the year ended
December 31, 2022, our Quarterly Report on Form 10-Q for the
quarter ending March 31, 2023 and in our other SEC filings. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and the Company undertakes no
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
DANYELZA®, OMBLASTYS® and Y-mAbs® are registered
trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney DuganVP, Head of Investor Relationscdu@ymabs.com
Grafico Azioni Y mAbs Therapeutics (NASDAQ:YMAB)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Y mAbs Therapeutics (NASDAQ:YMAB)
Storico
Da Set 2023 a Set 2024